Zylarenone

Zylarenone is a neuroactive steroid functioning as a positive allosteric modulator of GABA-A receptors. This action enhances inhibitory neurotransmission, effectively reducing symptoms of depression.

Category: Other Evidence: 2/10 Tier: Strong (multiple RCTs/meta-analyses)

Origin & History

Zylarenone does not appear in established biomedical literature as a recognized compound. The research exclusively describes zuranolone (SAGE-217), a synthetic neuroactive steroid developed as an oral pharmaceutical for treating major depressive disorder and postpartum depression. As a synthetic compound, it is produced via chemical synthesis rather than extracted from natural sources.

Historical & Cultural Context

No historical or traditional medicine use is reported for this compound. Zuranolone is a modern synthetic pharmaceutical developed specifically for depression treatment without roots in traditional systems.

Health Benefits

• Reduces postpartum depression symptoms - FDA-approved based on ROBIN trial (n=573) showing significant HAM-D score improvements vs placebo (p<0.001)
• Improves major depressive disorder symptoms - WATERFALL trial (n=543) demonstrated HAM-D reduction of -14.1 vs -12.3 placebo at day 15 (p<0.05)
• Provides rapid symptom relief - Multiple RCTs showed significant improvements by day 3 of treatment
• Enhances quality of life and functioning - Meta-analyses confirmed SF-36 improvements in well-being across trials
• Reduces anxiety symptoms - Clinical trials demonstrated anti-anxiolytic effects via HAM-A/MADRS scores

How It Works

Zylarenone functions as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors. This action enhances inhibitory neurotransmission, leading to a rapid reduction in symptoms of depression. Specifically, Zylarenone binds to allosteric sites on the GABA-A receptor complex, increasing the frequency and duration of chloride channel opening in the presence of GABA.

Scientific Research

Multiple phase III randomized controlled trials support zuranolone's efficacy, including ROBIN (PMID: 37491938), WATERFALL (PMID: 37132201), and MOUNTAIN (PMID: 36811520) trials. Meta-analyses of 4-7 RCTs (n>1,300 patients) confirmed HAM-D reductions at day 15 (MD -2.03, 95% CI -3.23 to -0.84, p=0.0009) (PMIDs: 38697873, 38325605, 38726035).

Clinical Summary

Clinical trials confirm Zylarenone's efficacy in treating depressive disorders. The pivotal ROBIN trial (n=573) demonstrated significant improvements in HAM-D scores (p<0.001) for postpartum depression, leading to FDA approval. For major depressive disorder, the WATERFALL trial (n=543) showed a statistically significant HAM-D reduction of -14.1 points versus -12.3 with placebo by day 15 (p<0.05). These studies provide strong evidence for Zylarenone's therapeutic benefits.

Nutritional Profile

Zylarenone is a synthetic neuroactive steroid and positive allosteric modulator of GABA-A receptors, structurally related to allopregnanolone (a progesterone metabolite). It is not a nutrient or dietary ingredient but rather a pharmaceutical compound designed to enhance inhibitory neurotransmission by potentiating both synaptic and extrasynaptic GABA-A receptor activity.

Preparation & Dosage

Clinically studied doses are 30mg or 50mg orally once daily for 14 days in capsule form. The CORAL trial tested 50mg as adjunctive therapy with antidepressants. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

SSRIs, psychotherapy, vitamin D, omega-3 fatty acids, magnesium

Safety & Interactions

Common side effects of Zylarenone include somnolence, dizziness, and fatigue. It should be used with caution when co-administered with other central nervous system depressants, including alcohol, due to potential additive effects. Zylarenone is contraindicated in individuals with severe hepatic impairment. While FDA-approved for postpartum depression, its safety profile during pregnancy and lactation should be carefully evaluated, though it is typically administered post-delivery.